Subsequent therapies for AL amyloidosis
| Subsequent therapy for AL, n (%)*† . | Bortezomib dose groups . | Total (n = 70) . | ||
|---|---|---|---|---|
| 1.6 mg/m2 QW (n = 18) . | 1.3 mg/m2 BIW (n = 34) . | Lower doses QW/BIW (n = 18) . | ||
| Any subsequent therapy for AL | 7 (39) | 21 (62) | 12 (67) | 40 (57) |
| Median (95% CI) time to subsequent therapy, months | 50.1 (11.4-NE) | 17.2 (12.7-30.4) | 29.0 (13.9-45.4) | 22.7 (16.9-40.6) |
| Agents received in any subsequent line | ||||
| Dexamethasone | 6 (33) | 13 (38) | 9 (50) | 28 (40) |
| Bortezomib | 5 (28) | 10 (29) | 4 (22) | 19 (27) |
| Lenalidomide | 2 (11) | 9 (26) | 7 (39) | 18 (26) |
| Cyclophosphamide | 4 (22) | 3 (9) | 2 (11) | 9 (13) |
| Melphalan | 2 (11) | 3 (9) | 3 (17) | 8 (11) |
| Thalidomide | 3 (17) | 1 (3) | 3 (17) | 7 (10) |
| Prednisone | 1 (6) | 3 (9) | 0 | 4 (6) |
| Investigational drug | 0 | 2 (6) | 1 (6) | 3 (4) |
| Bendamustine | 1 (6) | 1 (3) | 0 | 2 (3) |
| Cisplatin | 1 (6) | 1 (3) | 0 | 2 (3) |
| Doxorubicin | 1 (6) | 1 (3) | 0 | 2 (3) |
| Etoposide | 1 (6) | 1 (3) | 0 | 2 (3) |
| HDM-SCT | 0 | 0 | 2 (11)‡ | 2 (3) |
| Subsequent therapy for AL, n (%)*† . | Bortezomib dose groups . | Total (n = 70) . | ||
|---|---|---|---|---|
| 1.6 mg/m2 QW (n = 18) . | 1.3 mg/m2 BIW (n = 34) . | Lower doses QW/BIW (n = 18) . | ||
| Any subsequent therapy for AL | 7 (39) | 21 (62) | 12 (67) | 40 (57) |
| Median (95% CI) time to subsequent therapy, months | 50.1 (11.4-NE) | 17.2 (12.7-30.4) | 29.0 (13.9-45.4) | 22.7 (16.9-40.6) |
| Agents received in any subsequent line | ||||
| Dexamethasone | 6 (33) | 13 (38) | 9 (50) | 28 (40) |
| Bortezomib | 5 (28) | 10 (29) | 4 (22) | 19 (27) |
| Lenalidomide | 2 (11) | 9 (26) | 7 (39) | 18 (26) |
| Cyclophosphamide | 4 (22) | 3 (9) | 2 (11) | 9 (13) |
| Melphalan | 2 (11) | 3 (9) | 3 (17) | 8 (11) |
| Thalidomide | 3 (17) | 1 (3) | 3 (17) | 7 (10) |
| Prednisone | 1 (6) | 3 (9) | 0 | 4 (6) |
| Investigational drug | 0 | 2 (6) | 1 (6) | 3 (4) |
| Bendamustine | 1 (6) | 1 (3) | 0 | 2 (3) |
| Cisplatin | 1 (6) | 1 (3) | 0 | 2 (3) |
| Doxorubicin | 1 (6) | 1 (3) | 0 | 2 (3) |
| Etoposide | 1 (6) | 1 (3) | 0 | 2 (3) |
| HDM-SCT | 0 | 0 | 2 (11)‡ | 2 (3) |